{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:46:14Z","timestamp":1770741974828,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.sapharm.2020.06.003","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T19:33:14Z","timestamp":1591212794000},"page":"2005-2008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications"],"prefix":"10.1016","volume":"17","author":[{"given":"Callie G.","family":"Downs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler J.","family":"Varisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta S.","family":"Bapat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Douglas","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2020.06.003_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0989","article-title":"Trends in utilization of prescribed controlled substances in US commercially insured adults, 2004-2019","author":"Bykov","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"26","key":"10.1016\/j.sapharm.2020.06.003_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","article-title":"Vital signs: changes in opioid prescribing in the United States, 2006-2015","volume":"66","author":"Guy","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.sapharm.2020.06.003_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6901a1","article-title":"Opioid prescribing behaviors - prescription behavior surveillance system, 11 states, 2010-2016","volume":"69","author":"Strickler","year":"2020","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.sapharm.2020.06.003_bib4","first-page":"1","article-title":"Opioid prescribing patterns and overdose deaths in Texas","author":"Champagne-Langabeer","year":"2019","journal-title":"Subst Abuse"},{"issue":"2","key":"10.1016\/j.sapharm.2020.06.003_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/10826084.2018.1491052","article-title":"Perceived unintended consequences of prescription drug monitoring programs","volume":"54","author":"Yuanhong Lai","year":"2019","journal-title":"Subst Use Misuse"},{"issue":"5","key":"10.1016\/j.sapharm.2020.06.003_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3109\/01612840.2011.654046","article-title":"Prescription drug monitoring programs, a response to doctor shopping: purpose, effectiveness, and directions for future research","volume":"33","author":"Worley","year":"2012","journal-title":"Issues Ment Health Nurs"},{"issue":"11","key":"10.1016\/j.sapharm.2020.06.003_bib7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/pds.4300","article-title":"Research to support optimization of prescription drug monitoring programs","volume":"26","author":"Doyle","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.sapharm.2020.06.003_bib8","author":"World Health Organization Timeline - Covid-19"},{"key":"10.1016\/j.sapharm.2020.06.003_bib9","article-title":"On the frontline against COVID-19: community pharmacists' contribution during a public health crisis","author":"Cadogan","year":"2020","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.sapharm.2020.06.003_bib10","author":"Governor Abbott Declares State of Disaster","year":"2020"},{"key":"10.1016\/j.sapharm.2020.06.003_bib11","series-title":"Texas Medical Board Waiver for Chronic Pain Patients Granted by Governor Abbott","year":"2020"},{"key":"10.1016\/j.sapharm.2020.06.003_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/anae.15076","article-title":"Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel","author":"Shanthanna","year":"2020","journal-title":"Anaesthesia"},{"key":"10.1016\/j.sapharm.2020.06.003_bib14","author":"Texas GotSo"},{"key":"10.1016\/j.sapharm.2020.06.003_bib15","unstructured":"Texas Medical Board Passes Emergency Rules to Enforce Gov. Abbott's Executive Order GA-09 [press release]. Texas Medical Board, March 24, 2020."},{"issue":"2","key":"10.1016\/j.sapharm.2020.06.003_bib17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine use in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.sapharm.2020.06.003_bib18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1475-9276-12-18","article-title":"Patient-centred access to health care: conceptualising access at the interface of health systems and populations","volume":"12","author":"Levesque","year":"2013","journal-title":"Int J Equity Health"},{"issue":"18","key":"10.1016\/j.sapharm.2020.06.003_bib19","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1056\/NEJMp2003539","article-title":"Virtually perfect? Telemedicine for covid-19","volume":"382","author":"Hollander","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.sapharm.2020.06.003_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1357633X16674087","article-title":"Evaluating barriers to adopting telemedicine worldwide: a systematic review","volume":"24","author":"Kruse","year":"2018","journal-title":"J Telemed Telecare"},{"issue":"1","key":"10.1016\/j.sapharm.2020.06.003_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.mayocp.2014.09.010","article-title":"The epidemiology and economic consequences of pain","volume":"90","author":"Henschke","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.sapharm.2020.06.003_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.31887\/DCNS.2017.19.2\/dstein","article-title":"Epidemiology of anxiety disorders: from surveys to nosology and back","volume":"19","author":"Stein","year":"2017","journal-title":"Dialogues Clin Neurosci"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741120306860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741120306860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:23:41Z","timestamp":1761557021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741120306860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1551741120306860"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2020.06.003","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2020.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}